Table 3. Proportion of high responders in CARS scores bumetanide- and placebo-treated groups.

	Bumetanide 0.5 mg b.i.d. (N=20)	Bumetanide 1.0 mg b.i.d. (N=23)	Bumetanide 2.0 mg b.i.d. (N=22)	Placebo (N=23)	P-value (chi-square)	P-value (Fisher's exact test)
Responder
⩾4	11 (55.0%)	10 (43.5%)	11 (50%)	4 (17.4%)	0.0076	0.0125
⩾6	10 (50.0%)	5 (21.7%)	8 (36.4%)	1 (4.3%)	0.0041	0.0029
⩾8	7 (35.0%)	2 (8.7%)	3 (13.6%)	1 (4.3%)	0.1011	0.1701

Thirty bumetanide- and five placebo-treated showed an attenuation of more than 4 of whom 23 treated and only one placebo showed an amelioration of more than six Childhood Autism Rating Scale (CARS) scores, and 13 of these and only one placebo showed an attenuation of more than 8 points. The differences between placebo- and bumetanide-treated patients having more than 4, 6 or 8 points attenuation are highly significant.